1. BRAF exon 15 mutations in pediatric renal stromal tumors: prevalence in metanephric stromal tumors
- Author
-
Mariana M. Cajaiba, Samantha Gadd, Elizabeth J. Perlman, Min Yu, Lily Marsden, and Lawrence J. Jennings
- Subjects
Male ,Proto-Oncogene Proteins B-raf ,0301 basic medicine ,Pathology ,medicine.medical_specialty ,Stromal cell ,endocrine system diseases ,Congenital Mesoblastic Nephroma ,Biopsy ,DNA Mutational Analysis ,Metanephric adenoma ,Biology ,Polymerase Chain Reaction ,Pathology and Forensic Medicine ,law.invention ,Pathogenesis ,03 medical and health sciences ,Exon ,symbols.namesake ,0302 clinical medicine ,Gene Frequency ,law ,Biomarkers, Tumor ,medicine ,Humans ,Genetic Predisposition to Disease ,Nephroma, Mesoblastic ,Child ,Gene ,Polymerase chain reaction ,Sanger sequencing ,Age Factors ,Infant, Newborn ,Infant ,Exons ,medicine.disease ,Kidney Neoplasms ,digestive system diseases ,Phenotype ,030104 developmental biology ,Child, Preschool ,030220 oncology & carcinogenesis ,Mutation ,Cancer research ,symbols ,Female ,Stromal Cells - Abstract
Metanephric stromal tumors (MSTs) are rare renal stromal tumors that predominantly affect children. They belong to the metanephric family of tumors, along with metanephric adenofibroma and metanephric adenoma. The previous documentation of BRAF exon 15 mutations in 88% of metanephric adenomas and in isolated cases of metanephric adenofibroma prompted us to investigate the prevalence of these mutations in MSTs and in other pediatric renal stromal tumors. In this study, 17 MSTs, 22 congenital mesoblastic nephromas, and 6 ossifying renal tumors of infancy were selected for BRAF exon 15 testing. Tumor genomic DNA was extracted from formalin-fixed paraffin-embedded tissue, followed by polymerase chain reaction amplification and Sanger dideoxy sequencing with primers flanking the BRAF exon 15 gene. BRAF exon 15 mutations were found in 11 (65%) of the 17 cases of MST, all corresponding to a thymidine-to-adenine substitution at codon 600 (BRAF V600E). All other renal stromal tumors tested were negative for BRAF exon 15 mutations. In conclusion, BRAF V600E mutations are encountered in most MSTs, supporting a link with other metanephric tumors and suggesting a clonal event possibly affecting primordial renal cells. In addition, BRAF V600E mutations have been associated with oncogene-induced senescence in other benign tumors, providing clues to the pathogenesis of metanephric neoplasms in keeping with their overall benign behavior. Our results also suggest a potential diagnostic use for BRAF exon 15 mutations in differentiating MSTs from other pediatric renal stromal tumors, particularly in limited samples.
- Published
- 2017
- Full Text
- View/download PDF